IOL Chemicals and Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
IOLCP · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.6 pts more than Nifty Microcap 250 and 4.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
IOL Chemicals and Pharmaceuticals reported Q1 FY26 standalone revenue from operations of Rs 551.69 Cr, up ~9.8% YoY from Rs 502.38 Cr, while profit after tax rose ~14.4% YoY to Rs 33.96 Cr (from Rs 29.68 Cr), with EPS at Rs 1.16 vs Rs 1.01. EBITDA margin improved to about 12.6% from 11.6% a year ago, helped by stronger Pharma segment performance (segment PBT of Rs 40.09 Cr). The Board approved forming a wholly owned subsidiary in the United Kingdom to strengthen its UK and EU footprint. It also approved setting up Unit 9B dedicated to Minoxidil and its intermediates with 120 MTPA capacity, at a small capex of Rs 5.50 Cr to be funded entirely from internal accruals, targeted for completion by December 2025. The statutory auditor issued an unmodified limited review report on both standalone and consolidated results.
Steady double-digit profit growth and margin expansion signal healthy operational momentum, while the modest Minoxidil capex funded internally and the new UK subsidiary point to controlled, low-risk expansion that should be viewed positively by shareholders.